Where does Bioverativ USA Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Bioverativ USA Inc. ranks #31,041 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Bioverativ USA Inc. hold?

Bioverativ USA Inc. holds 8 US utility patents granted between 2019 and 2025, spanning 6 technology areas.

What is Bioverativ USA Inc.'s Innovation Score?

Bioverativ USA Inc. has an Innovation Score of 27.3 out of 100 (23rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Bioverativ USA Inc. focus on?

Bioverativ USA Inc.'s top technology area is C07K (Peptides) with 8 patents, ranking #1,078 of 3,615 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Bioverativ USA Inc.'s patent grant rate increasing or decreasing?

Bioverativ USA Inc.'s recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Bioverativ USA Inc.'s patents?

Bioverativ USA Inc.'s patents average 15.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Bioverativ USA Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Bioverativ USA Inc.

USPTO PatentsView assignee record - 8 granted patents across 6 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Bioverativ ranks #31,041 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 6 technology areas.

#31,041
of 49,997 US assignees by volume: 23rd percentile
by Innovation Score (27.3/100): 15.6
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31041 · US Corporation #31,041 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,041/49,997
PHOTO-FINISH Biohaven Pharmaceuti…
CPC-NARROW C07K · 6 areas
INNOV-THIN 27.3/100
CLAIMS-RICH 15.6 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Biohaven Pharmaceutical Holding Company Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Bioverativ’s 27.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (28%) Velocity 1.7 pts (6%) Breadth 8.7 pts (32%) Claim depth 9.4 pts (34%)

Qualcomm Incorporated · highest

85
Bioverativ USA · this assignee

27
3D Lighting… · lowest

7

What this shows Bioverativ's Innovation Score is 27.3/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Bioverativ?

Each dot is one of Bioverativ’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Bioverativ’s own 15.6 claims/patent is at or below the 17.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Bioverativ vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Bioverativ's grants concentrate

Bioverativ USA Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2020. By volume, Bioverativ sits between Biohaven Pharmaceutical Holding Company Ltd. and Blackstar Enterprises Group, Inc..

Bioverativ's three-year grant acceleration

Bioverativ USA Inc. shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Biohaven Pharmace…

8
Biometry

8
Bionic Power

8
Bioriginal Food &…

8
Bird Rides

8
Birdie Love

8
Black Diamond Cre…

8
Blackstar Enterpr…

8
Bioverativ USA ◀

8

What this shows Bioverativ holds 8 patents at rank #31,068, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Bioverativ

By rank, the assignees closest to #31,068 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Bioverativ's primary technology class.

Bioverativ's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Bioverativ USA Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	25.0%
2020	1	12.5%
2021	1	12.5%
2022	1	12.5%
2025partial year	3	37.5%

Which technologies does Bioverativ USA Inc. patent most?

C07K - Peptides 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

C12Y - Enzymes 4

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Bioverativ USA Inc.'s patent record in context - here's where to go next.

Bioverativ USA Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #31,041 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Bioverativ USA Inc. against Biohaven Pharmaceutical Holding Company Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.